China channel feed – Endpoints News

China channel feed

The coming glut? Cancer cell therapy trials are booming as China rivals US on new projects

6 years ago

Ready to harvest its PD-L1, Alphamab reloads with $60M to nurture the bispecific patch

6 years ago

‘I was shocked’: Controversy brews at Emory after prominent Chinese neuroscientists are ousted over disclosure issues

6 years ago

Top 5 Chinese players: What does Everest's landmark deal with Immunomedics say about the flurry of in-licensing to China?

7 years ago

Nine listings and $3.8B later, HKEX celebrates one-year biotech anniversary with $194M CRO IPO

7 years ago

MD Anderson tries to assure researchers in town hall meeting that Asian ‘ethnicity’ is not the driving force behind purge

7 years ago

Lilly to sell legacy antibiotics, Ceclor and Vancocin, to China-based partner in $375M deal

7 years ago

Three Asian MD Anderson scientists purged in wake of NIH-directed investigations on data violations

7 years ago

Chinese pharmaceutical manufacturer in spotlight after welding accident kills 10

7 years ago

This Chinese pharma filed for an IPO last September. Seven months and a $283M investment later, they are back at the HKEX

7 years ago

Chinese player joins a growing group of biotechs buying into Synaffix's ADC linker tech

7 years ago

Vas Narasimhan has high hopes for Novartis' China drive as a blockbuster drug gets a nod

7 years ago

Eight months after filing for IPO, the maker of China's Ebola vaccine joins HKEX with $161M raise

7 years ago

Shanghai-based cancer drugmaker Abbisko lines up $42M B round as it makes a leap for the clinic

7 years ago

Oncology dominates a 'Cambrian explosion' in China's drug pipeline as McKinsey guru bets on a burst of innovation

7 years ago

Backed by OrbiMed, Lilly and now Advantech, China's InventisBio loads up $70M to propel cancer, metabolic pipeline

7 years ago

Abpro bags $60M in near-term R&D cash in tie-up with China's NJCTTQ, with eyes on bispecific T cell engagers

7 years ago

In HKEX's first test in 2019, CStone seeks up to $304M in IPO fortune

7 years ago

Hillhouse Capital endorses China-based HaiHe Biopharma's cancer pipeline in $146M round

7 years ago

Zai Lab nabs speedy China regulatory review for PARP drug Zejula

7 years ago

Mass cloning for neuro research? Chinese scientists report birth of five gene-edited monkeys

7 years ago

Chinese government probe condemns Jiankui He as rogue scientist pursuing 'illegal' work on gene-edited babies

7 years ago

In a first, China’s BeiGene scores FDA ‘breakthrough’ status for BTK inhibitor — potential rival for Imbruvica

7 years ago

Ramping up in-house drug development, API maker BrightGene bags $80M round led by Sequoia China

7 years ago

First page Previous page 20 21 222324 25 26 Next page Last page